Serum retinol binding protein-4 and the risk of hypothyroidism in Egyptian diabetic patients with cardiovascular manifestations

Hanan A. Sleem; Heba I. Hamed; Rasha A. El-Saeed; Magdy M. Youssef

doi:10.53730/ijhs.v6nS4.9668

Authors

Hanan A. Sleem Biochemistry Division, Chemistry Department, Faculty of Science, Mansoura University, Egypt
Heba I. Hamed Biochemistry Department, National Institute of Diabetes and Endocrinology, Egypt
Rasha A. El-Saeed
Rasha_elsaeed@hotmail.com
Lecturer of Biochemistry, Biochemistry Division, Chemistry Department, Faculty of Science, Mansoura University, Mansoura, Egypt
Magdy M. Youssef Biochemistry Division, Chemistry Department, Faculty of Science, Mansoura University, Egypt

Keywords:

T2DM, CVD, hypothyroidism, retinol binding protein 4

Abstract

Retinol binding protein-4 (RBP4) levels have been associated with patients of type 2 diabetes (T2DM) including insulin resistance (IR), dyslipidemia, and cardiovascular disease (CVD). The present study examined the relationship between serum levels of RBP4 and the risk factors related to hypothyroidism (Hypo) and CVD in diabetic Egyptian patients. A total of 96 subjects were recruited and divided into 8 groups. Subjects were assessed for different biochemical parameters. In addition, serum levels of RBP4 were measured using specific immunoassays. There was a highly statistically significant difference in fasting blood glucose (FBG) and hemoglobin A1C (HbA1c) between the different patient groups and the control group. Thyroid stimulating hormone (TSH) concentration in the (T2DM+Hyp) group was considerably higher than in the other groups. There were statistically significant variations in TSH levels between all groups and controls. The mean RBP4 value in Group5 (T2DM+Hyp+CVD) was significantly higher than in the other groups. In (T2DM+Hypo+CVD) group, the receiver operating characteristic (ROC) curve revealed that RBP4 had a higher area under curve (AUC), making it a powerful discriminator of those diseases.

Downloads

Download data is not yet available.

References

Yang, M., Chen, Y., Zhao, T., Wang, Z., 2020. Effect of astaxanthin on metabolic cataract in rats with type 1 diabetes mellitus. Exp. Mol. Pathol. 113, 104372. https://doi.org/ 10.1016/j.yexmp.2020.104372.

Shawki, H. A., E. M.Abo-Hashem, M. M. Youssef, M. Shahin and R. Elzehery "Association of transcription factor 7-like 2 (rs7903146) gene polymorphism with diabetic retinopathy." Ophthalmic Genetics 41(5): 420-426, (2020).

Shawki, H. A., Abo-Hashem, E. M., Youssef, M. M., Shahin, M., & Elzehery, R. (2022). PPARɣ2, aldose reductase, and TCF7L2 gene polymorphisms: relation to diabetes mellitus. Journal of Diabetes & Metabolic Disorders, 1-10.‏

A. M. Rychter et al., “Is the retinol-binding protein 4 a possible risk factor for cardiovascular diseases in obesity?,” Int. J. Mol. Sci., vol. 21, no. 15, p. 5229, 2020.

Y. Chen, P. Lv, M. Du, Z. Liang, M. Zhou, and D. Chen, “Increased retinol-free RBP4 contributes to insulin resistance in gestational diabetes mellitus,” Arch. Gynecol. Obstet., vol. 296, no. 1, pp. 53–61, 2017.

B. Qin, M. M. Polansky, D. Harry, and R. A. Anderson, “Green tea polyphenols improve cardiac muscle mRNA and protein levels of signal pathways related to insulin and lipid metabolism and inflammation in insulin‐resistant rats,” Mol. Nutr. Food Res., vol. 54, no. S1, pp. S14–S23, 2010.

J. Gómez‐Ambrosi et al., “Serum retinol‐binding protein 4 is not increased in obesity or obesity‐associated type 2 diabetes mellitus, but is reduced after relevant reductions in body fat following gastric bypass,” Clin. Endocrinol. (Oxf)., vol. 69, no. 2, pp. 208–215, 2008.

R. Kadiyala, R. Peter, and O. E. Okosieme, “Thyroid dysfunction in patients with diabetes: clinical implications and screening strategies,” Int. J. Clin. Pract., vol. 64, no. 8, pp. 1130–1139, 2010.

D. Khandelwal and N. Tandon, “Overt and subclinical hypothyroidism,” Drugs, vol. 72, no. 1, pp. 17–33, 2012.

S. Kalra, S. Aggarwal, and D. Khandelwal, “Thyroid dysfunction and type 2 diabetes mellitus: screening strategies and implications for management,” Diabetes Ther., vol. 10, no. 6, pp. 2035–2044, 2019.

Trinder P “Blood sugar estimation by GOD-POD method”. Ann Clin Biochem; 6: 24–27, (1969).

Jeppsson JO, Jerntorp P, Sundkvist G, Englund H, & Nylund V “Measurement of hemoglobin A1c by a new liquid chromatographic assay”: methodology, clinical utility, and relation to glucose tolerance evaluated. Clinical Chemistry; 32(10): 1867–1872, (1986).

Flier JS, Kahn CR, & Roth J “Receptors, antireceptor antibodies and mechanisms of insulin resistance”. N Engl J Med;300(8):413-9. doi: 10.1056/NEJM197902223000808. PMID: 366414, (1979).

Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. “Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man”. Diabetologia, 28(7), 412–419. https://doi.org/10.1007/BF00280883, (1985).

Allain CC, Poon LS, Chan CSG, Richmond W, & Fu PC “Enzymatic determination of total serum cholesterol”. Clinical Chemistry; 20(4): 470–475, (1974).

McGowan MW, Artiss JD, Strandbergh DR, & Zak B “A peroxidase-coupled method for the colorimetric determination of serum triglycerides”. Clinical Chemistry; 29(3): 538–542, (1983).

Lopez-Virella MF, Stone S, Eills S, & Collwel JA“Determination of HDL-cholesterol using enzymatic method”. Clin. Chem; 23: 882–884, (1977).

Friedwald WT, Leve RI, & Fredrichson DS “Estimation of concentration of low-density lipoproteins separated by three different methods”. Clin. Chem; 18: 499–502, (1972)

Burger HG, & Patel YC “Thyrotrophin releasing hormone-- TSH”. Clin Endocrinol Metab. (1):83-100, (1977).

Pedersen KO “A systematic study of variables affecting protein binding of thyroxine and triiodothyronine in serum”. Scand J Clin Lab Invest; 34(3):247-55, (1974).

Nelson JC, & Wilcox RB “Analytical performance of free and total thyroxine assays”. Clin Chem ;42(1):146-54, (1996).

T. E. Graham, C. J. Wason, M. Blüher, and B. B. Kahn, “Shortcomings in methodology complicate measurements of serum retinol binding protein (RBP4) in insulin-resistant human subjects,” Diabetologia, vol. 50, no. 4, pp. 814–823, 2007.

S. U. Ogbonna and I. U. Ezeani, “Risk factors of thyroid dysfunction in patients with type 2 diabetes mellitus,” Front. Endocrinol. (Lausanne)., vol. 10, p. 440, 2019.

B. Biondi, G. J. Kahaly, and R. P. Robertson, “Thyroid dysfunction and diabetes mellitus: two closely associated disorders,” Endocr. Rev., vol. 40, no. 3, pp. 789–824, 2019.

S. I. Taylor, Z. S. Yazdi, and A. L. Beitelshees, “Pharmacological treatment of hyperglycemia in type 2 diabetes,” J. Clin. Invest., vol. 131, no. 2, 2021.

S. Paul, A. Ali, and R. Katare, “Molecular complexities underlying the vascular complications of diabetes mellitus–A comprehensive review,” J. Diabetes Complications, vol. 34, no. 8, p. 107613, 2020.

Z. Li, M. L. Deng, C.-H. Tseng, and D. Heber, “Hypertriglyceridemia is a practical biomarker of metabolic syndrome in individuals with abdominal obesity,” Metab. Syndr. Relat. Disord., vol. 11, no. 2, pp. 87–91, 2013.

M. Wang et al., “Cancer risk among patients with type 2 diabetes mellitus: a population-based prospective study in China,” Sci. Rep., vol. 5, no. 1, pp. 1–7, 2015.

B. I. Joffe and L. A. Distiller, “Diabetes mellitus and hypothyroidism: strange bedfellows or mutual companions?,” World J. Diabetes, vol. 5, no. 6, p. 901, 2014.

B. Gopinath, G. Liew, A. Kifley, and P. Mitchell, “Thyroid dysfunction and ten-year incidence of age-related macular degeneration,” Invest. Ophthalmol. Vis. Sci., vol. 57, no. 13, pp. 5273–5277, 2016.

P.-H. Groop, C. Forsblom, and M. C. Thomas, “Mechanisms of disease: pathway-selective insulin resistance and microvascular complications of diabetes,” Nat. Clin. Pract. Endocrinol. Metab., vol. 1, no. 2, pp. 100–110, 2005.

C. Ferri et al., “Relationship between insulin resistance and nonmodulating hypertension: linkage of metabolic abnormalities and cardiovascular risk.,” Diabetes, vol. 48, no. 8, pp. 1623–1630, 1999.

E. H. Elgazar, N. E. Esheba, S. A. Shalaby, and W. F. Mohamed, “Thyroid dysfunction prevalence and relation to glycemic control in patients with type 2 diabetes mellitus,” Diabetes Metab. Syndr. Clin. Res. Rev., vol. 13, no. 4, pp. 2513–2517, 2019.

N. Kandasamy et al., “A study on correlation between HbA1c levels with TSH levels in patients with hypothyroidism and type 2 diabetes mellitus,” J. Evol. Med. Dent. Sci., vol. 5, no. 54, pp. 3645–3653, 2016.

C. Soma, “Studies on Prevalence of Cardio metabolic Risk Factors and Anaemia in Relation to Antioxidant Status of Postmenopausal Women from Different Ethnic Communities.” BLDE (Deemed to be University), 2015.

A. K. Singh, S. K. Singh, N. Singh, N. Agrawal, and K. Gopal, “Obesity and dyslipidemia,” Int J Biol Med Res, vol. 2, no. 3, pp. 824–828, 2011.

Y. Wang et al., “Molecular and functional characterization of the retinol-binding protein 4 (RBP4) in hepatocytes of Schizothorax prenanti in response to palmitic acid,” Fish Physiol. Biochem., vol. 48, no. 2, pp. 449–459, 2022.

W. Zhou, S.-D. Ye, and W. Wang, “Elevated retinol binding protein 4 levels are associated with atherosclerosis in diabetic rats via JAK2/STAT3 signaling pathway,” World J. Diabetes, vol. 12, no. 4, p. 466, 2021.

H.-X. Sun et al., “Serum retinol-binding protein 4 is associated with the presence and severity of coronary artery disease in patients with subclinical hypothyroidism,” Aging (Albany NY), vol. 11, no. 13, p. 4510, 2019.

V. Lambadiari et al., “Serum levels of retinol-binding protein-4 are associated with the presence and severity of coronary artery disease,” Cardiovasc. Diabetol., vol. 13, no. 1, pp. 1–8, 2014.

L. Chaker et al., “Subclinical hypothyroidism and the risk of stroke events and fatal stroke: an individual participant data analysis,” J. Clin. Endocrinol. Metab., vol. 100, no. 6, pp. 2181–2191, 2015.

A. Di Pino and R. A. DeFronzo, “Insulin resistance and atherosclerosis: implications for insulin-sensitizing agents,” Endocr. Rev., vol. 40, no. 6, pp. 1447–1467, 2019.

H. Yanai and H. Yoshida, “Beneficial effects of adiponectin on glucose and lipid metabolism and atherosclerotic progression: mechanisms and perspectives,” Int. J. Mol. Sci., vol. 20, no. 5, p. 1190, 2019.

R. A. Schmiedt et al., “Insulin resistance as risk factor for the development of type 2 diabetes mellitus: a systematic approach,” Acta Marisiensis-Seria Medica, vol. 67, no. 4, 2021.

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Health and treatment of diabetes mellitus. International Journal of Health Sciences, 5(1), i-v. https://doi.org/10.53730/ijhs.v5n1.2864

Mahardika, I. M. R., Suyasa, I. G. P. D., Kamaryati, N. P., & Wulandari, S. K. (2021). Health literacy is strongest determinant on self-monitoring blood glucose (SMBG) type 2 DM patients during COVID-19 pandemic at public health centre in Tabanan Regency. International Journal of Health & Medical Sciences, 4(3), 288-297. https://doi.org/10.31295/ijhms.v4n3.1752